Capricor Therapeutics Book Value 2011-2026 | CAPR

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Capricor Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
22.6 M	11.8 M	31.4 M	28.2 M	6.84 M	4.62 M	11.2 M	-4 M	-1.03 M	-6.25 M	-535 K	-167 K	831 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
31.4 M	-6.25 M	8.11 M

Quarterly Book Value Capricor Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
83.9 M	105 M	128 M	145 M	68.3 M	11.5 M	18.4 M	22.6 M	-1.79 M	2.73 M	6.21 M	11.8 M	15.4 M	18.7 M	24.6 M	31.4 M	36.7 M	33.4 M	36.4 M	28.2 M	28.2 M	28.2 M	28.2 M	6.84 M	6.84 M	6.84 M	6.84 M	4.62 M	4.62 M	4.62 M	4.62 M	11.2 M	11.2 M	11.2 M	11.2 M	-4 M	-4 M	-4 M	-4 M	-1.03 M	-1.03 M	-1.03 M	-1.03 M	-6.25 M	-6.25 M	-6.25 M	-6.25 M	-535 K	-535 K	-535 K	-535 K	4.89 M	-167 K	-167 K	-167 K	831 K	831 K	831 K	1.37 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
145 M	-6.25 M	16.3 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	-24.2 M	-	17.91 %	$ 11.1 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Axcella Health AXLA	4.16 M	-	-16.42 %	$ 249 M	USA
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
AVEO Pharmaceuticals AVEO	45.9 M	-	-	$ 521 M	USA
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Agenus AGEN	314 M	$ 3.27	-1.8 %	$ 1.17 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Agios Pharmaceuticals AGIO	1.19 B	$ 28.72	-5.0 %	$ 1.66 B	USA
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Завод ДИОД DIOD	-243 M	-	-	-	Russia
Фармсинтез LIFE	29.8 B	-	-	-	Russia
Baudax Bio BXRX	-24.2 M	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	49.1 M	-	-10.95 %	$ 876 K	USA